A Study to Test BI 655130 in Patients With a Flare-up of a Skin Disease Called Generalized Pustular Psoriasis

  • STATUS
    Recruiting
  • End date
    Mar 15, 2021
  • participants needed
    51
  • sponsor
    Boehringer Ingelheim
Updated on 22 November 2020
Investigator
Boehringer Ingelheim Call Center
Primary Contact
Nihon University Itabashi Hospital (2.3 mi away) Contact
+70 other location

Summary

To evaluate efficacy, safety, and tolerability of BI 655130 compared to placebo in patients with Generalized Pustular Psoriasis (GPP) presenting with an acute flare of moderate to severe intensity

Details
Treatment Placebo, BI 655130, Spesolimab
Clinical Study IdentifierNCT03782792
SponsorBoehringer Ingelheim
Last Modified on22 November 2020

Adding a note
adding personal notes guide

Select a piece of text and start making personal notes.

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

Study

user name

Annotated by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No made yet